 ContraFect Corporation CFRX, a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents DLAs, including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced that it has extended early access to exebacase to individual named patients with chronic post-operative prosthetic joint infections PJIs under Temporary Authorizations for Use ATUs from the French National Agency for Medicines and Health Products Safety ANSM in collaboration with Dr. Tristan Ferry at the Hôpital de la Croix Rousse in Lyon, France. Based on promising clinical signals in these exebacase-treated patients, temporary authorization for use of exebacase has now been extended to patients with Staphylococcal PJI occurring early in the postoperative period, to potentially avoid significant loss of function. 